Market News AIOpen the app

The U.K. has approved Pharming's Joenja to treat kids aged 4 to 11 with APDS.

TrialRead the original at globenewswire.com
Good for PHAR

The U.K. approval expands the age range for Joenja to children aged 4 to 11 with APDS. This gives Pharming a new group of eligible patients, though the story reports no sales or access results.

PHAR · Pharming Group N.V.

AI read · Good for PHAR

The AI's read

This adds younger children with APDS to the group that may be treated with Joenja in the U.K. Pharming plans to work with the NHS to help eligible children get access. The story gives no sales figures or access results, so the added patient group is positive news, not proof of increased sales.

Get alerts for PHAR

Follow Pharming Group N.V. (PHAR) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for PHAR
Free on the App Store and Google Play, or on the web.